Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Inhalation Sciences: key patent approved in Europe

(Stockholm, 30 June 2020) Inhalation Sciences (ISAB) has received European approval, with no restrictions, for a key patent that covers the company’s unique simplified method to accomplish so called “regional targeting”— or being able to selectively direct aerosol exposures to the different main regions in the lung.Regional targeting gives new opportunities to map how either drug substances or air pollutants work in the lungs. The patent with reference number EP2173419 has previously been approved in the US and China, but is now also approved on the important European market without

Presentation of Gränges’ half-year report for January–June 2020

Gränges’ half-year report for the period January–June 2020 will be published at 07.30 CEST on Thursday, 16 July 2020. The webcast will be available on www.granges.com/investors. To participate in the conference call, please call +46 8 56642651 (Sweden), +44 3333000804 (United Kingdom) or +1 6319131422 (United States). PIN code: 69788601#. Please call a few minutes before the conference call begins. A presentation will be available on the company’s website before the webcast begins. For further information, please contact:Johan Dufvenmark, VP Group Treasury & Investor Relations

Change in the total number of shares and votes in Recipharm AB (publ)

As of 30 June 2020, the total number of shares in Recipharm AB (publ) (“Recipharm”) amounts to 100,990,187 shares, divided into 21,311,998 shares of series A and 79,678,189 shares of series B. The total number of votes in Recipharm as of 30 June 2020 amounts to 292,798,169. The number of shares and votes in Recipharm has increased as a result of the registration of 6,089,140 shares of series A and 22 600 368 shares of series B subscribed for by the exercise of subscription rights in the ongoing rights issue in Recipharm, which was resolved on May 26, 2020.  For more information

Positive results from human PK study assessing Orexo’s intranasal nalmefene formulations for opioid overdose reversal

· Preliminary data indicate extensive and rapid absorption of OX125 across all formulations · Positive results underline the applicability of Orexo’s novel intranasal drug delivery platform Uppsala, Sweden - June 30, 2020 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces positive results from its human pharmacokinetic (PK) study of OX125. The study was a cross-over, comparative bioavailability study in healthy volunteers to assess nalmefene absorption from three development formulations of OX125, Orexo's wholly-owned nasal nalmefene product, compared to a nalmefene

Conversion of shares

According to Essity’s articles of association, owners of Class A shares have the right to have such shares converted to Class B shares. Conversion reduces the total number of votes in the company. When such a conversion has occurred, the company is obligated by law to disclose any such changes in this manner.In June, at the request of shareholders 1,912,497 Class A shares were converted to Class B shares. The total number of votes in the company thereafter amounts to 1,257,975,156.The total number of registered shares in the company amounts to 702,342,489 of which 61,736,963 are Class A

Oncopeptides submits a New Drug Application to the FDA for accelerated approval of melflufen in triple-class refractory multiple myeloma patients

STOCKHOLM — June 30, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the Company submits a New Drug Application (NDA) to the U.S. Food and Drug Administration, FDA, for accelerated approval of melflufen (INN melphalan flufenamide) in combination with dexamethasone for the treatment of adult patients with multiple myeloma whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD38 monoclonal antibody (i.e., triple-class refractory multiple myeloma patients).Melflufen is the lead candidate coming out of the

Starbreeze resolves on a fully guaranteed rights issue of SEK 250 million to enable full focus on continued development of PAYDAY 3 and strengthening financial position

The Board of Directors of Starbreeze AB (publ) (“Starbreeze” or the “Company”) has today resolved on a rights issue of class A and class B shares of approximately SEK 250 million before transaction costs (the “Rights Issue”). The proceeds from the Rights Issue will be used to strengthen the financial position and for operational purposes, enabling the Company to fully focus on continued development of PAYDAY 3, and support the Company to fulfil its obligations to its creditors in line with the reorganization plan and the judicial composition. The Rights Issue is supported by the Company’s

Lindab will close down IMP Klima Group

Production of large air handling units will be discontinued After a strategic performance review, Lindab has today decided to close down IMP Klima Group, consisting of LINDAB, klima sistemi, d.o.o. in Slovenia and its subsidiaries in Serbia, Montenegro and Bosnia-Herzegovina. The production of air handling units in Slovenia will be discontinued by the end of 2020. Lindab acquired IMP Klima in 2015 to establish a presence in the air handling unit market. It is a highly competitive market with customized solutions. IMP Klima has shown poor sales development and it has been a loss-making

Order worth 6 million SEK for Tier1 supplier in USA

FlexQube has received an order for a German based company, who is setting up a new plant to manufacture automotive parts in Southeast USA, worth 6 million SEK. The order consists of modular FlexQube trolleys in four different versions in combination with the Liftrunner Mother Daughter tugger train system. IPW Lift Techs is managing the deal and FlexQube is selling the products through them. The order will be delivered during the third quarter 2020. “Once again we win a large tugger train order after showing the customer how strong the combination of the unique and modular FlexQube

SSM acquires all shares in half-owned JV company Studentbacken including ca 280 building rights in Bromma, Sollentuna and Täby

SSM Holding AB, Sweden’s leading residential developer within smart, affordable homes, has acquired all of the shares in the half-owned joint venture company Studentbacken that SSM has run together with Student Hill since 2013. The acquisition also includes about 280 building rights in three projects currently being developed within the joint venture: Kandidaten, The Loft and Tentafabriken. The purchase price amounts to ca 2.0 MSEK and the transaction will be carried out in July 2020.Today, SSM has acquired all of the shares in the half-owned joint venture company Studentbacken.Since 2013,

Konftel receives Frost & Sullivan award for best video-capable conference product

Konftel , a global leader in products for effective distance meetings, has been presented with a Best Practices Award by the distinguished US analysis firm Frost & Sullivan. The award relates to the company’s Konftel 800 conference phone, which delivers outstanding sound in video conferences. Frost & Sullivan judges the Konftel C50800 Hybrid video package to be the most attractive option on the market.“Considering the generous specifications and sturdy build quality, Frost & Sullivan believes the Konftel C50800 Hybrid audio-video bundle offers the best value for

Gasum opened a new shipping fuel station at Ports of Stockholm

Gasum’s new bunkering station for liquefied gas was taken into use in mid-June. The station is located at Port of Nynäshamn, Sweden on the premises of Ports of Stockholm. The new station includes new bunkering solutions enabling ships to bunker environmentally friendly fuel faster than ever.After a year of construction, the new bunkering station is finally ready to serve existing and new customers. It enables bunkering at high speed from two trucks at the same time. The station set-up and the specialized trucks now being used allows bunkering to take place at the same time as unloading or

Change of number of shares and votes in Green Landscaping Group AB (publ)

In June 2020, the number of shares and votes in Green Landscaping Group AB (publ) ("Green Landscaping" or the “Company") has changed as a result of the rights issue carried out by Green Landscaping in order to strengthen the Company's balance sheet by repaying the bridge financing raised in connection with the acquisition of GAST Entreprenør AS and P.A.R.K. i Syd AB and to increase the Company's cash and cash equivalents in readiness for future acquisitions. Through the rights issue, the number of shares and votes in Green increased by 9,236,026. As of 30 June 2020, there is in total 46,

Nordic Nanovector to amend PARADIGME trial protocol to expand eligible patient population

Oslo, Norway, 30 June 2020 Nordic Nanovector ASA (OSE: NANO) announces that it will amend the trial protocol for its PARADIGME trial to broaden the inclusion criteria and expand the pool of eligible patients with the aim of increasing the present rate of enrolment. This decision has been made based on the company’s reviewed discussions with the US Food and Drug Administration (FDA). PARADIGME is the company’s ongoing pivotal, global, randomised Phase 2b trial investigating Betalutin® ([177]Lu-lilotomab satetraxetan) as a single administration in 3[rd]-line relapsed/refractory

Neste, HERE and PTV: navigators do not always propose the CO\2\ friendliest route

Neste Corporation, Press Release, 30 June 2020 at 7.30 (EET) A collaboration between Neste, HERE Technologies, and PTV Group indicates that traffic-related CO\2\ emissions can be reduced by choosing the right driving route, especially in urban areas on short trips with private cars. Earlier this spring, Neste and its partners tested the emissions of different route options by installing measuring equipment in vehicles. According to the gathered data, navigators do not always propose the CO\2\ friendliest route* option.  “Road transportation accounts for a significant part

Vestas develops wind energy solution for two high-wind sites in Japan

News release from Vestas Asia PacificJapan, 30 June 2020 In partnership with Tokyu Land Corporation and Japan Wind Development, Vestas has secured a 76 MW order for Chitose Wind Farm and Noheji Mutsuwan Wind Farm in the Aomori prefecture of Japan. Due to the typhoon and earthquake prone environment of the region, extended collaboration between all project partners was required when designing a turbine solution to maximise wind capture in the sites’ challenging wind and weather conditions. The order includes the supply and supervision of four V117-3.45 MW and six V105-3.45 MW

Kommuniké från årsstämma i Divio Technologies AB (publ)

ResultatdispositionÅrsstämman i Divio Technologies AB (publ) beslutade att fastställa resultat- och balansräkningar för 2019. Styrelsen och den verkställande direktören beviljades ansvarsfrihet för 2019. Stämman beslöt att disponera över bolagets resultat i enlighet med styrelsens förslag i årsredovisningen, vilket innebärande ingen vinstutdelning.  Val av styrelseordförandeGustav Martner meddelade att han på grund av andra åtagande inte är tillgänglig för fortsatt arbete i Divio och avgår därmed både som ordförande och styrelseledamot. Måns Danielson valdes till ny

Outcome of Catena Media’s fully guaranteed rights issue of units oversubscribed, fulfilment of condition under written procedure and record date for amortisation

Catena Media plc (Nasdaq Stockholm: CTM) Catena Media plc (“Catena Media” or the “Company”) today announces the outcome of the fully guaranteed rights issue of units (“Units”) consisting of hybrid capital securities (“Capital Securities”) and warrants (“Warrants”) (the “Rights Issue”) for which the subscription period ended on 26 June 2020. Units for a total amount of approximately SEK 593 million, corresponding to approximately 86.7 per cent. of the Rights Issue, were subscribed for by exercise of unit subscription rights. Applications for subscription without exercise of unit

Pharmacolog i Uppsala AB (publ) intends to carry out a directed news issue of units

INFORMATIONEN I DETTA PRESSMEDDELANDE FÅR INTE OFFENTLIGGÖRAS, PUBLICERAS ELLER DISTRIBUERAS, DIREKT ELLER INDIREKT, TILL AUSTRALIEN, HONG KONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, USA ELLER NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION AV INFORMATIONEN SKULLE VARA I STRID MED ELLER KRÄVA REGISTRERING ENLIGT GÄLLANDE REGLER.Pharmacolog i Uppsala AB (publ) (“Pharmacolog” eller “Bolaget”) avser att genomföra en riktad nyemission av units, bestående av två (2) aktier av serie B och en (1) teckningsoption av serie TO1, motsvarade ett värde

Magnolia Bostad sells 380 residential units in Ursvik

Magnolia Bostad has sold an additional project to Heimstaden Bostad, this time in Ursvik, Sundbyberg’s municipality. The sale is consisting of around 380 residencies, a nursery school, 8 retail premises and 168 garage spaces. The estimated property value at completion will be around SEK 1,0 billion.The sale is taking place as a corporate transaction and refers to the Brygghuset 1, 2 & 3 properties, a total of about 32,970 m[2] GFA. The project has a zoning plan in force and was acquired during the quarter. Revenue recognition will take place during Q2 2020.The area is located in Västra

Oncopeptides strengthens the pre-clinical development and takes over Kancera´s Solna-based laboratory for drug development as of July 1

STOCKHOLM — June 29, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the Company has agreed with Kancera to take over Kancera’s drug development facility in Solna, Sweden.  The agreement is an important step in the development of Oncopeptides’ pre-clinical operations and marks an additional reinforcement of the Company´s research capacity. Oncopeptides recruits several employees with pre-clinical expertise from Kancera and takes over the lease contract for laboratory facilities as well as equipment.“I am very glad that we have gained the opportunity to recruit highly

Investigations against Caverion closed in Germany

Caverion Corporation Stock exchange release 29 June 2020 at 6.30 p.m. EESTInvestigations against Caverion closed in Germany The public prosecutor's office in Munich has informed that no further investigative measures are intended and that no formal fine proceedings against Caverion will be initiated related to possible suspected bribery in Germany. More information on the potential investigations has been given in a stock exchange release published by Caverion on 28 April 2016.  CAVERION CORPORATION Distribution: NASDAQ Helsinki, principal media, www.caverion.com

There are no items matching the current filter
There are no more items matching the current filter
Back to top